{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:23:40Z","timestamp":1792268620623,"version":"4.4.0"},"reference-count":151,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T00:00:00Z","timestamp":1736640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Phosphodiesterase-4 (PDE4) is involved in the synthesis of inflammatory cytokines that mediate several chronic inflammatory disorders, including psoriasis and atopic dermatitis. In recent years, the therapeutic armamentarium in dermatology has expanded with the introduction of PDE4 inhibitors, both in oral and topical formulations. PDE4 inhibitors have gained increasing interest due to their remarkable safety record and ease of prescription, as evidenced by the recent influx of literature detailing its off-label uses. Apremilast was the first PDE4 inhibitor approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for psoriasis, psoriatic arthritis, and oral ulcers of Behcet\u2019s disease. Off-label use has been reported in diverse dermatological conditions, including aphthous stomatitis, chronic actinic dermatitis, atopic dermatitis, cutaneous sarcoidosis, hidradenitis suppurativa, lichen planus, and discoid lupus erythematosus. Roflumilast is a PDE4 inhibitor that was approved by the FDA and the EMA as an oral treatment of chronic obstructive pulmonary disease. Since patent expiration, several generic formulations of oral roflumilast have become available, and various studies have documented its off-label use in psoriasis and other dermatological conditions such as hidradenitis suppurativa, recurrent oral aphthosis, nummular eczema, lichen planus, and Beh\u00e7et\u2019s disease. Topical roflumilast has received FDA approval for treatment of plaque psoriasis and seborrheic dermatitis. The favorable safety profile encourages its long-term use as an alternative to corticosteroids, addressing the chronic nature of many dermatological conditions. New oral PDE4 inhibitors are being developed, such as orismilast (LEO-32731), mufemilast (Hemay005), difamilast (OPA-15406) or lotamilast (E6005\/RVT-501), among others. This narrative review provides a comprehensive synthesis of the pharmacology, clinical efficacy, safety profile, and practical considerations regarding the oral and topical use of PDE4 inhibitors in dermatology.<\/jats:p>","DOI":"10.3390\/pharmaceutics17010091","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T11:31:31Z","timestamp":1736767891000},"page":"91","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4979-3593","authenticated-orcid":false,"given":"Elena","family":"Carmona-Rocha","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"},{"name":"Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain"},{"name":"Unitat Docent Hospital Universitari Sant Pau, Facultat de Medicina, Universitat Aut\u00f2noma de Barcelona, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3421-7756","authenticated-orcid":false,"given":"Llu\u00eds","family":"Rusi\u00f1ol","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"},{"name":"Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain"},{"name":"Unitat Docent Hospital Universitari Sant Pau, Facultat de Medicina, Universitat Aut\u00f2noma de Barcelona, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Llu\u00eds","family":"Puig","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"},{"name":"Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain"},{"name":"Unitat Docent Hospital Universitari Sant Pau, Facultat de Medicina, Universitat Aut\u00f2noma de Barcelona, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ujiie, H., Rosmarin, D., Sch\u00f6n, M.P., St\u00e4nder, S., Boch, K., Metz, M., Maurer, M., Thaci, D., Schmidt, E., and Cole, C. (2022). Unmet Medical Needs in Chronic, Non-Communicable Inflammatory Skin Diseases. Front. Med., 9.","DOI":"10.3389\/fmed.2022.875492"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/VHRM.S343319","article-title":"Cardiovascular Disease-Associated Skin Conditions","volume":"18","author":"Hojman","year":"2022","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s13555-017-0205-2","article-title":"Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis","volume":"7","author":"Alcusky","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/1346-8138.16746","article-title":"A Discrete Choice Experiment on Oral and Injection Treatment Preferences among Moderate-to-severe Psoriasis Patients in Japan","volume":"50","author":"Komine","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e12932","DOI":"10.1111\/dth.12932","article-title":"Biologics in Dermatology: What Does the Future Hold?","volume":"32","author":"Yavuz","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0889-857X(05)70365-3","article-title":"Methotrexate Hepatotoxicity","volume":"23","author":"West","year":"1997","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0270-9295(03)00090-1","article-title":"Cyclosporine Nephrotoxicity","volume":"23","author":"Burdmann","year":"2003","journal-title":"Semin. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_9","unstructured":"FDA (2024, December 01). OTEZLA\u00ae (Apremilast): Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/205437s012lbl.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s40265-015-0463-1","article-title":"Roflumilast: A Review in COPD","volume":"75","year":"2015","journal-title":"Drugs"},{"key":"ref_11","unstructured":"FDA (2024, December 01). ZORYVE\u00ae (Roflumilast): Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215985s007lbl.pdf."},{"key":"ref_12","unstructured":"FDA (2024, December 01). ZORYVE\u00ae (Roflumilast): Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217242s000lbl.pdf."},{"key":"ref_13","unstructured":"FDA (2024, December 01). EUCRISA\u00ae (Crisaborole): Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/207695s012lbl.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e14261","DOI":"10.1111\/dth.14261","article-title":"Apremilast in Dermatology: A Review of Literature","volume":"33","author":"Nassim","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ad.2023.09.005","article-title":"Roflumilast T\u00f3pico y Oral En Dermatolog\u00eda. Una Revisi\u00f3n Narrativa","volume":"115","author":"Gimeno","year":"2024","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_16","first-page":"364","article-title":"Therapeutic Benefit of PDE4 Inhibitors in Inflammatory Diseases","volume":"8","author":"Dastidar","year":"2007","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_17","first-page":"S252","article-title":"Phosphodiesterase Inhibitors","volume":"147","author":"Spina","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1124\/pharmrev.120.000273","article-title":"The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitorss","volume":"73","author":"Paes","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/exd.13808","article-title":"The Role of Phosphodiesterase 4 in the Pathophysiology of Atopic Dermatitis and the Perspective for Its Inhibition","volume":"28","author":"Hanifin","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2249.1995.tb03123.x","article-title":"The Role of CAMP Regulation in Controlling Inflammation","volume":"101","author":"Moore","year":"1995","journal-title":"Clin. Exp. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/187152807780077318","article-title":"Highly Selective Phosphodiesterase 4 Inhibitors for the Treatment of Allergic Skin Diseases and Psoriasis","volume":"6","author":"Hoppmann","year":"2007","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1067\/mai.2001.119555","article-title":"Cyclic Nucleotide Phosphodiesterases","volume":"108","author":"Essayan","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1085\/jgp.201311083","article-title":"Cyclic AMP Compartments and Signaling Specificity: Role of Cyclic Nucleotide Phosphodiesterases","volume":"143","author":"Conti","year":"2014","journal-title":"J. General. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1007\/s13555-023-01054-3","article-title":"Next Generation PDE4 Inhibitors That Selectively Target PDE4B\/D Subtypes: A Narrative Review","volume":"13","author":"Blauvelt","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100S","DOI":"10.1111\/1523-1747.ep12462340","article-title":"Relationship between Increased Cyclic AMP-Phosphodiesterase Activity and Abnormal Adenylyl Cyclase Regulation in Leukocytes from Patients with Atopic Dermatitis","volume":"98","author":"Hanifin","year":"1992","journal-title":"J. Investig. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1038\/jid.1995.17","article-title":"Monocyte Phosphodiesterase Abnormalities and Dysregulation of Lymphocyte Function in Atopic Dermatitis","volume":"105","author":"Hanifin","year":"1995","journal-title":"J. Investig. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/archdermatol.2012.812","article-title":"A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults","volume":"148","author":"Samrao","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Li, H., Zuo, J., and Tang, W. (2018). Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01048"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Krueger, J.G., Kavanaugh, A., and Gladman, D.D. (2017). 5413 Apremilast Reduces IL-17F, IL-17A, IL-22, and TNF-a Plasma pro-Tein Levels in Patients with Moderate to Severe Plaque Psoriasis: Pharmacodynamic and Correlative Results from Phase 2\/3 Studies. J. Am. Acad. Dermatol., 76.","DOI":"10.1016\/j.jaad.2017.04.201"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"906349","DOI":"10.1155\/2015\/906349","article-title":"The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)","volume":"2015","author":"Schafer","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis and Current Skin Involvement: A Phase III, Randomised, Controlled Trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an Oral Phosphodiesterase 4 (PDE4) Inhibitor, in Patients with Moderate to Severe Plaque Psoriasis: Results of a Phase III, Randomized, Controlled Trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and Safety of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis over 52 Weeks: A Phase III, Randomized Controlled Trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jaad.2023.11.068","article-title":"Efficacy and Safety of Apremilast in Pediatric Patients with Moderate-to-Severe Plaque Psoriasis: 16-Week Results from SPROUT, a Randomized Controlled Trial","volume":"90","author":"Fiorillo","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_36","unstructured":"(2024, December 01). Judith Stewart Otezla FDA Approval History. Available online: https:\/\/www.drugs.com."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jid.2018.10.043","article-title":"A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis","volume":"139","author":"Simpson","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for Moderate Hidradenitis Suppurativa: Results of a Randomized Controlled Trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.2147\/CCID.S390591","article-title":"Evaluation of the Efficacy and Safety of Apremilast in the Management of Lichen Planus","volume":"15","author":"Viswanath","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_40","first-page":"1224","article-title":"Apremilast for Discoid Lupus Erythematosus: Results of a Phase 2, Open-Label, Single-Arm, Pilot Study","volume":"11","author":"Strober","year":"2012","journal-title":"J. Drugs Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdcr.2021.11.009","article-title":"Apremilast as a Treatment for Morphea: A Case Series","volume":"19","author":"Koschitzky","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archdermatol.2011.301","article-title":"Efficacy and Safety of Apremilast in Chronic Cutaneous Sarcoidosis","volume":"148","author":"Baughman","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1684\/ejd.2018.3280","article-title":"A Case of Anti-Laminin \u03931 (P200) Pemphigoid with Psoriasis Vulgaris Successfully Treated with Apremilast","volume":"28","author":"Waki","year":"2018","journal-title":"Eur. J. Dermatol."},{"key":"ref_44","first-page":"e15258","article-title":"Successful Treatment of Erythema Nodosum Leprosum with Apremilast","volume":"35","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zhang, Q., Yu, L., Wan, L., Chen, L., and Chen, J. (2024). Case Report: Managing Pemphigus Foliaceus Using Apremilast without Systemic Glucocorticosteroids or Immunosuppressive Agents. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1408116"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Delvaux, C., Bohelay, G., Sitbon, I.-Y., Soued, I., Alexandre, M., Cucherousset, J., Gilardin, L., Diep, A., Caux, F., and Le Roux-Villet, C. (2024). Activity of Apremilast in a Patient with Severe Pemphigus Vulgaris: Case Report. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1404185"},{"key":"ref_47","first-page":"1107","article-title":"Recalcitrant Hailey-Hailey Disease With Satisfactory Response to Apremilast","volume":"115","year":"2023","journal-title":"Actas Dermosifiliogr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3109\/00498254.2011.604745","article-title":"Disposition, Metabolism and Mass Balance of [(14)C]Apremilast Following Oral Administration","volume":"41","author":"Hoffmann","year":"2011","journal-title":"Xenobiotica"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/cpdd.109","article-title":"The Pharmacokinetic Effect of Coadministration of Apremilast and Methotrexate in Individuals with Rheumatoid Arthritis and Psoriatic Arthritis","volume":"3","author":"Liu","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Blair, H.A. (2024). Apremilast: First Pediatric Approval. Paediatr. Drugs.","DOI":"10.1007\/s40272-024-00668-0"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40265-017-0709-1","article-title":"Apremilast: A Review in Psoriasis and Psoriatic Arthritis","volume":"77","author":"Keating","year":"2017","journal-title":"Drugs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of Psoriatic Arthritis in a Phase 3 Randomised, Placebo-Controlled Trial with Apremilast, an Oral Phosphodiesterase 4 Inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast Monotherapy in DMARD-Naive Psoriatic Arthritis Patients: Results of the Randomized, Placebo-Controlled PALACE 4 Trial","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaad.2017.01.052","article-title":"Long-Term Safety and Tolerability of Apremilast in Patients with Psoriasis: Pooled Safety Analysis for \u2265156 Weeks from 2 Phase 3, Randomized, Controlled Trials (ESTEEM 1 and 2)","volume":"77","author":"Crowley","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1111\/jdv.16439","article-title":"Real-World Effectiveness and Safety of Apremilast in Psoriasis at 52 Weeks: A Retrospective, Observational, Multicentre Study by the Spanish Psoriasis Group","volume":"34","author":"Armesto","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1111\/jdv.18166","article-title":"A Real-World, Non-Interventional, Prospective Study of the Effectiveness and Safety of Apremilast in Bio-Na\u00efve Adults with Moderate Plaque Psoriasis Treated in the Routine Care in Greece\u2014The \u201cAPRAISAL\u201d Study","volume":"36","author":"Ioannides","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jdin.2020.10.012","article-title":"Effectiveness and Clinical Predictors of Drug Survival in Psoriasis Patients Receiving Apremilast: A Registry Analysis","volume":"2","author":"Graier","year":"2021","journal-title":"JAAD Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"452","DOI":"10.23736\/S2784-8671.23.07638-7","article-title":"Efficacy, Tolerability and Patient\u2019s Satisfaction for the Treatment of Moderate to Severe Plaque Psoriasis with Apremilast in the Real-Life Setting of Campania Region, Italy","volume":"158","author":"Licata","year":"2023","journal-title":"Ital. J. Dermatol. Venereol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1111\/jdv.14256","article-title":"Apremilast and Suicidality\u2014A Retrospective Analysis of Three Large Databases: The FAERS, EudraVigilance and a Large Single-Centre US Patient Population","volume":"31","author":"Vakharia","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Beh\u00e7et\u2019s Syndrome\u2014A Phase 2, Placebo-Controlled Study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of Apremilast for Oral Ulcers in Beh\u00e7et\u2019s Syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_62","first-page":"69","article-title":"Apremilast in Refractory Orogenital Ulcers and Other Manifestations of Beh\u00e7et\u2019s Disease. A National Multicentre Study of 51 Cases in Clinical Practice","volume":"38","author":"Espinosa","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Lopalco, G., Morrone, M., Venerito, V., Cantarini, L., Emmi, G., Espinosa, G., Lled\u00f3, G.M., Mosca, M., Talarico, R., and Cauli, A. (2024). Exploring Relief for Beh\u00e7et\u2019s Disease Refractory Oral Ulcers: A Comparison of TNF Inhibitors versus Apremilast. Rheumatology, keae274.","DOI":"10.1093\/rheumatology\/keae274"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1111\/jdv.18906","article-title":"Apremilast 30\u2009Mg Twice Daily Combined with Dupilumab for the Treatment of Recalcitrant Moderate-to-Severe Atopic Dermatitis","volume":"37","author":"Cunningham","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2020.08.113","article-title":"Long-Term Treatment with Apremilast in Hidradenitis Suppurativa: A 2-Year Follow-up of Initial Responders","volume":"85","author":"Aarts","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/jpet.116.232819","article-title":"Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes","volume":"358","author":"Dong","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_67","first-page":"1165","article-title":"Roflumilast Altana Pharma","volume":"3","author":"Reid","year":"2002","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/0091270006294529","article-title":"Dose-Proportional Intraindividual Single- and Repeated-Dose Pharmacokinetics of Roflumilast, an Oral, Once-Daily Phosphodiesterase 4 Inhibitor","volume":"47","author":"Bethke","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1476-5381.2011.01218.x","article-title":"Update on Roflumilast, a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease","volume":"163","author":"Rabe","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_70","first-page":"149","article-title":"Roflumilast (Daliresp): A Novel Phosphodiesterase-4 Inhibitor for the Treatment of Severe Chronic Obstructive Pulmonary Disease","volume":"37","author":"Baye","year":"2012","journal-title":"Pharm. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/dom.12839","article-title":"The PDE4 Inhibitor Roflumilast Reduces Weight Gain by Increasing Energy Expenditure and Leads to Improved Glucose Metabolism","volume":"19","author":"Kahles","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1753465812466167","article-title":"Efficacy and Safety of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis","volume":"7","author":"Oba","year":"2013","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1097\/MJT.0000000000000465","article-title":"Treating 2 Diseases With 1 Drug: PDE-4 Inhibitor for COPD and Psoriasis","volume":"24","author":"Michels","year":"2017","journal-title":"Am. J. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/bjd.20602","article-title":"Complete Clearance of Severe Plaque Psoriasis with 24 Weeks of Oral Roflumilast Therapy","volume":"185","author":"Egeberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_75","first-page":"e429","article-title":"Long-Term Clearance of Severe Plaque Psoriasis with Oral Roflumilast","volume":"37","author":"Meteran","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2240456","DOI":"10.1080\/09546634.2023.2240456","article-title":"Oral Roflumilast as a Therapeutic Option for Psoriasis, What Role Does It Have? Case Report and Literature Review","volume":"34","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/bjd.21744","article-title":"Considerable Improvement in Hidradenitis Suppurativa with Oral Roflumilast Therapy","volume":"187","author":"Ring","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/ced\/llae229","article-title":"Treatment of Palmoplantar Psoriasis with Oral Roflumilast: A Case Series","volume":"49","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Gyldenl\u00f8ve, M., Meteran, H., S\u00f8rensen, J.A., Fage, S., Yao, Y., Lindhardsen, J., Nissen, C.V., Todberg, T., Thomsen, S.F., and Skov, L. (2023). Efficacy and Safety of Oral Roflumilast for Moderate-to-Severe Psoriasis\u2014A Randomized Controlled Trial (PSORRO). Lancet Reg. Health-Eur., 30.","DOI":"10.1016\/j.lanepe.2023.100639"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaad.2024.02.036","article-title":"Effects of Oral Roflumilast Therapy on Body Weight and Cardiometabolic Parameters in Patients with Psoriasis\u2014Results from a Randomized Controlled Trial (PSORRO)","volume":"91","author":"Fage","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Gyldenl\u00f8ve, M., S\u00f8rensen, J.A., Thomsen, S.F., Fage, S., Iversen, L., Skov, L., Zachariae, C., Egeberg, A., and Nielsen, M.L. (2024). Improvements in Patient-Reported Outcomes with Oral Roflumilast for Psoriasis: Results from a Randomized Controlled Trial (PSORRO). J. Eur. Acad. Dermatol. Venereol.","DOI":"10.1111\/jdv.20343"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jaad.2024.01.018","article-title":"A Randomized, Controlled Pilot Study of Oral Roflumilast Compared with Intramuscular Methotrexate for Plaque and Scalp Psoriasis","volume":"90","author":"Saadi","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Holgersen, N., Nielsen, V.W., Ring, H.C., Egeberg, A., Thyssen, J.P., Gyldenl\u00f8ve, M., and Thomsen, S.F. (2024). Effectiveness, Safety and Drug Survival of Oral Roflumilast for Hidradenitis Suppurativa. J. Eur. Acad. Dermatol. Venereol.","DOI":"10.1111\/jdv.20222"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/ced\/llae284","article-title":"Treatment of Beh\u00e7et Disease with Oral Roflumilast, an Observational Study","volume":"50","author":"Carazo","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/ced\/llad189","article-title":"Refractory Beh\u00e7et Disease Succesfully Treated with Roflumilast","volume":"48","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_86","first-page":"e390","article-title":"Treatment of Recurrent Aphthous Stomatitis with Oral Roflumilast, a Multicenter Observational Study","volume":"63","author":"Bagan","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bjd.21044","article-title":"Rapid Improvement of Idiopathic Aphthous Ulcers with Oral Roflumilast Therapy","volume":"187","author":"Meteran","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_88","first-page":"e765","article-title":"Rapid Clearing of Refractory Nummular Dermatitis with Oral Roflumilast Therapy","volume":"36","author":"Zachariae","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_89","first-page":"1554","article-title":"Is Roflumilast a Feasible Alternative for the Treatment of Mucocutaneous Lichen?","volume":"21","year":"2023","journal-title":"JDDG\u2014J. Ger. Soc. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/ced\/llad041","article-title":"Severe and Therapeutic Challenging Oral Erosive Lichen Planus Treated with Oral Roflumilast","volume":"48","author":"Fage","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jdcr.2024.02.004","article-title":"Refractory Erythema Annulare Centrifugum Treated with Roflumilast","volume":"47","author":"Calderon","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_92","first-page":"164","article-title":"Successful Treatment of Erythema Nodosum Leprosum with Upadacitinib and Roflumilast","volume":"64","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jid.2016.06.619","article-title":"PDE4 Inhibition as Potential Treatment of Epidermolysis Bullosa Acquisita","volume":"136","author":"Koga","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2000073","article-title":"Trial of Roflumilast Cream for Chronic Plaque Psoriasis","volume":"383","author":"Lebwohl","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2022.15632","article-title":"Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials","volume":"328","author":"Lebwohl","year":"2022","journal-title":"JAMA"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40257-022-00739-3","article-title":"Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial","volume":"24","author":"Draelos","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/bjd\/ljad182","article-title":"Once-Daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A Randomized, Double-Blind, Vehicle-Controlled Phase IIb Study","volume":"189","author":"Kircik","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jaad.2023.12.065","article-title":"Roflumilast Foam 0.3% for Adolescent and Adult Patients with Seborrheic Dermatitis: A Randomized, Double-Blinded, Vehicle-Controlled, Phase 3 Trial","volume":"90","author":"Blauvelt","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamadermatol.2024.3121","article-title":"Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children","volume":"160","author":"Simpson","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/JPER.20-0858","article-title":"Inhibitory Effect of Roflumilast on Experimental Periodontitis","volume":"93","author":"Liu","year":"2022","journal-title":"J. Periodontol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1097\/MJT.0000000000001678","article-title":"Roflumilast 0.3% Cream: A Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis","volume":"30","author":"Nicolas","year":"2023","journal-title":"Am. J. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/PTT.S303634","article-title":"Phosphodiesterase-4 Inhibition in Psoriasis","volume":"11","author":"Milakovic","year":"2021","journal-title":"Psoriasis"},{"key":"ref_103","unstructured":"(2024, December 01). Judith Stewart Eucrisa FDA Approval History. Available online: https:\/\/www.drugs.com."},{"key":"ref_104","unstructured":"(2024, December 01). Staquis (Crisaborole) Approval by European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/staquis."},{"key":"ref_105","first-page":"1394","article-title":"A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis","volume":"14","author":"Spelman","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1001\/jamadermatol.2018.2397","article-title":"Topical Crisaborole-A Potential Treatment for Recalcitrant Palmoplantar Psoriasis","volume":"154","author":"Robbins","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/09546634.2018.1480747","article-title":"Treatment of Psoriasis with Crisaborole","volume":"30","author":"Lee","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"ref_108","first-page":"e809","article-title":"Topical Crisaborole Is an Efficacious Steroid-Sparing Agent for Treating Mild-to-Moderate Seborrhoeic Dermatitis","volume":"34","author":"Oak","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e15893","DOI":"10.1111\/dth.15893","article-title":"Successful Treatment of Pediatric Lichen Planus with Topical Crisaborole","volume":"35","author":"Lu","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/ijd.17268","article-title":"Disseminated Superficial Porokeratosis: Two Case Reports of Successful Treatment with 2% Crisaborole Ointment","volume":"63","author":"Liang","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1111\/1346-8138.17205","article-title":"A Case of Plasma Cell Vulvitis Successfully Treated with Crisaborole","volume":"51","author":"He","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1111\/jdv.17938","article-title":"Crisaborole: An Emerging Therapy for Prurigo Pigmentosa","volume":"36","author":"Xu","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/bjd\/ljac092","article-title":"Successful Treatment of Vitiligo with Crisaborole Ointment: A Report of Two Cases","volume":"188","author":"Sun","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2023.12.048","article-title":"Efficacy and Safety of Crisaborole Ointment, 2%, in Participants Aged \u226545 Years with Stasis Dermatitis: Results from a Fully Decentralized, Randomized, Proof-of-Concept Phase 2a Study","volume":"90","author":"Silverberg","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_115","first-page":"1108","article-title":"Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study","volume":"14","author":"Murrell","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and Safety of Crisaborole Ointment, a Novel, Nonsteroidal Phosphodiesterase 4 (PDE4) Inhibitor for the Topical Treatment of Atopic Dermatitis (AD) in Children and Adults","volume":"75","author":"Paller","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.det.2024.05.001","article-title":"Topical Therapy for Atopic Dermatitis: What Is New and the New Paradigm","volume":"42","author":"Buethe","year":"2024","journal-title":"Dermatol. Clin."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2019.06.1288","article-title":"Crisaborole 2% Ointment for the Treatment of Intertriginous, Anogenital, and Facial Psoriasis: A Double-Blind, Randomized, Vehicle-Controlled Trial","volume":"82","author":"Hashim","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e15424","DOI":"10.1111\/dth.15424","article-title":"Successful Treatment with Crisaborole for Facial Lesions Refractory to Adalimumab in a Man with Psoriasis: A Case Report","volume":"35","author":"Liu","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2023.11.005","article-title":"Orismilast in Moderate-to-Severe Psoriasis: Efficacy and Safety from a 16-Week, Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, and Phase 2b Trial (IASOS)","volume":"90","author":"Warren","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/jdv.19770","article-title":"Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa: Week 16 Data from OSIRIS, a Phase 2a, Open-Label, Single-Centre, Single-Arm, Dose-Finding Clinical Trial","volume":"38","author":"Frederiksen","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_122","unstructured":"Miyazawa, Y. (2023). Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor. Patients with Plaque Psoriasis at EADV Congress 2023, Meiji Seika Pharma Co., Ltd."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaad.2021.10.027","article-title":"Difamilast Ointment in Adult Patients with Atopic Dermatitis: A Phase 3 Randomized, Double-Blind, Vehicle-Controlled Trial","volume":"86","author":"Saeki","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s13555-022-00751-9","article-title":"Difamilast Ointment in Japanese Adult and Pediatric Patients with Atopic Dermatitis: A Phase III, Long-Term, Open-Label Study","volume":"12","author":"Saeki","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjd.20655","article-title":"Difamilast, a Selective Phosphodiesterase 4 Inhibitor, Ointment in Paediatric Patients with Atopic Dermatitis: A Phase III Randomized Double-Blind, Vehicle-Controlled Trial","volume":"186","author":"Saeki","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/09546634.2016.1157257","article-title":"Efficacy of a Novel Phosphodiesterase Inhibitor, E6005, in Patients with Atopic Dermatitis: An Investigator-Blinded, Vehicle-Controlled Study","volume":"27","author":"Ohba","year":"2016","journal-title":"J. Dermatol. Treat."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/1346-8138.12534","article-title":"Safety and Efficacy of Topical E6005, a Phosphodiesterase 4 Inhibitor, in Japanese Adult Patients with Atopic Dermatitis: Results of a Randomized, Vehicle-Controlled, Multicenter Clinical Trial","volume":"41","author":"Furue","year":"2014","journal-title":"J. Dermatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/1346-8138.13231","article-title":"Effect of Topical Phosphodiesterase 4 Inhibitor E6005 on Japanese Children with Atopic Dermatitis: Results from a Randomized, Vehicle-Controlled Exploratory Trial","volume":"43","author":"Nemoto","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jamadermatol.2023.4990","article-title":"Efficacy and Safety of PF-07038124 in Patients with Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial","volume":"160","author":"Eichenfield","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Cheng, Y.-D., Hwang, T.-L., Wang, H.-H., Pan, T.-L., Wu, C.-C., Chang, W.-Y., Liu, Y.-T., Chu, T.-C., and Hsieh, P.-W. (2011). Anthranilic Acid-Based Inhibitors of Phosphodiesterase: Design, Synthesis, and Bioactive Evaluation. Org. Biomol. Chem., 9.","DOI":"10.1039\/c1ob05714f"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"176202","DOI":"10.1016\/j.ejphar.2023.176202","article-title":"ME3183, a Novel Phosphodiesterase-4 Inhibitor, Exhibits Potent Anti-Inflammatory Effects and Is Well Tolerated in a Non-Clinical Study","volume":"962","author":"Kaji","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cpdd.1351","article-title":"Safety, Tolerability, and Pharmacokinetics of a Novel Oral Phosphodiesterase 4 Inhibitor, ME3183: First-in-Human Phase 1 Study","volume":"13","author":"Kato","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3000605231169445","DOI":"10.1177\/03000605231169445","article-title":"Difamilast for the Treatment of Atopic Dermatitis","volume":"51","author":"Freitas","year":"2023","journal-title":"J. Int. Med. Res."},{"key":"ref_134","unstructured":"(2024, December 01). Organon Completes Acquisition of Dermavant, Including Innovative Dermatologic Therapy, VTAMA\u00ae (Tapinarof) Cream, 1%. Available online: Https:\/\/Www.Organon.Com\/News\/Organon-Completes-Acquisition-of-Dermavant-Including-Innovative-Dermatologic-Therapy-Vtama-Tapinarof-Cream-1\/#:~:Text=Organon%20Completes%20Acquisition%20of%20Dermavant,)%20Cream%2C%201%25%20%7C%20Organon."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jdermsci.2014.09.010","article-title":"Effect of the Phosphodiesterase 4 Inhibitor E6005 on Nerve Growth Factor Elevation in Irritated Skin of NC\/Nga Mice","volume":"76","author":"Ishii","year":"2014","journal-title":"J. Dermatol. Sci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/exd.12377","article-title":"Topical E6005, a Novel Phosphodiesterase 4 Inhibitor, Attenuates Spontaneous Itch-Related Responses in Mice with Chronic Atopy-like Dermatitis","volume":"23","author":"Andoh","year":"2014","journal-title":"Exp. Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1021\/jm500378a","article-title":"Discovery and Early Clinical Development of 2-{6-[2-(3,5-Dichloro-4-Pyridyl)Acetyl]-2,3-Dimethoxyphenoxy}-N-Propylacetamide (LEO 29102), a Soft-Drug Inhibitor of Phosphodiesterase 4 for Topical Treatment of Atopic Dermatitis","volume":"57","author":"Felding","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41021-017-0077-9","article-title":"Giemsa-Stained Pseudo-Micronuclei in Rat Skin Treated with Vitamin D3 Analog, Pefcalcitol","volume":"39","author":"Takeiri","year":"2017","journal-title":"Genes. Environ."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1124\/jpet.103.059097","article-title":"Anti-Inflammatory Potential of the Selective Phosphodiesterase 4 Inhibitor N-(3,5-Dichloro-Pyrid-4-Yl)-[1-(4-Fluorobenzyl)-5-Hydroxy-Indole-3-Yl]-Glyoxylic Acid Amide (AWD 12-281), in Human Cell Preparations","volume":"308","author":"Draheim","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1211\/jpp.57.12.0011","article-title":"The Phosphodiesterase 4 Inhibitor AWD 12-281 Is Active in a New Guinea-Pig Model of Allergic Skin Inflammation Predictive of Human Skin Penetration and Suppresses Both Th1 and Th2 Cytokines in Mice","volume":"57","author":"Hoppmann","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1211\/0022357021585","article-title":"AWD 12-281, a Highly Selective Phosphodiesterase 4 Inhibitor, Is Effective in the Prevention and Treatment of Inflammatory Reactions in a Model of Allergic Dermatitis","volume":"55","author":"Gorr","year":"2003","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1765633","DOI":"10.1080\/21688370.2020.1765633","article-title":"DRM02, a Novel Phosphodiesterase-4 Inhibitor with Cutaneous Anti-Inflammatory Activity","volume":"8","author":"Hunt","year":"2020","journal-title":"Tissue Barriers"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"6783","DOI":"10.1096\/fj.201800354","article-title":"Topical Application of Anthranilate Derivatives Ameliorates Psoriatic Inflammation in a Mouse Model by Inhibiting Keratinocyte-derived Chemokine Expression and Neutrophil Infiltration","volume":"32","author":"Lin","year":"2018","journal-title":"FASEB J."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Difficult-to-Treat Nail and Scalp Psoriasis: Results of 2 Phase III Randomized, Controlled Trials (ESTEEM 1 and ESTEEM 2)","volume":"74","author":"Rich","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaad.2023.10.020","article-title":"Efficacy and Safety of Apremilast in Patients with Moderate-to-Severe Genital Psoriasis: Results from DISCREET, a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial","volume":"90","author":"Merola","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast Is a Selective PDE4 Inhibitor with Regulatory Effects on Innate Immunity","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell Signal"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"220206","DOI":"10.1183\/16000617.0206-2022","article-title":"Phosphodiesterase 4B Inhibition: A Potential Novel Strategy for Treating Pulmonary Fibrosis","volume":"32","author":"Kolb","year":"2023","journal-title":"Eur. Respir. Rev."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.4049\/jimmunol.178.8.4820","article-title":"Differential Expression and Function of Phosphodiesterase 4 (PDE4) Subtypes in Human Primary CD4+ T Cells: Predominant Role of PDE4D","volume":"178","author":"Peter","year":"2007","journal-title":"J. Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/jdv.17769","article-title":"Apremilast Effectively Inhibits TNF\u03b1-Induced Vascular Inflammation in Human Endothelial Cells","volume":"36","author":"Otto","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40257-017-0302-0","article-title":"Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis","volume":"19","author":"Torres","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Picchianti-Diamanti, A., Spinelli, F.R., Rosado, M.M., Conti, F., and Lagan\u00e0, B. (2021). Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052638"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/1\/91\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:27:15Z","timestamp":1759919235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/1\/91"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,12]]},"references-count":151,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["pharmaceutics17010091"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17010091","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,12]]}}}